艾迪药业业绩快报：2025年净亏损1973.37万元

Core Viewpoint - The company reported significant improvements in its financial performance for the fiscal year 2025, with total revenue increasing substantially and a notable reduction in net losses compared to the previous year [1][2]. Financial Performance - Total revenue for the year reached 721 million yuan, representing a year-on-year increase of 72.49% [1]. - Operating profit was 47.746 million yuan, marking a turnaround from a loss to profitability [1]. - Total profit amounted to 24.3042 million yuan, also indicating a shift from loss to profit [1]. - The net profit attributable to the parent company's owners was -19.7337 million yuan, with the loss margin decreasing by 86.02% year-on-year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was -20.9272 million yuan, with the loss margin decreasing by 85.90% year-on-year [1][2]. Asset and Equity Position - Total assets at the end of the reporting period were 1.916 billion yuan, an increase of 2.50% from the beginning of the period [1]. - Equity attributable to the parent company's owners was 964 million yuan, a decrease of 1.67% from the beginning of the period [1]. Key Drivers of Performance - The increase in revenue was primarily driven by higher income from innovative HIV drugs and the consolidation of Nanda Pharmaceutical's operational data, which contributed approximately 255 million yuan to gross profit [2]. - Sales expenses increased by approximately 92 million yuan due to intensified promotion of new drugs and the consolidation of Nanda Pharmaceutical's operational data [2]. - Asset impairment losses decreased by approximately 48 million yuan as market expansion and expectations stabilized [2].